Driving Global Healthcare progress with smart partnerships & innovation

About Us

Driven by Smart Deal-Making

VyaRx is a forward-thinking B2B pharmaceutical company driven by strategic partnerships and offering access to a robust portfolio across 15+ therapy areas. Anchored by over four decades of global leadership, we bring specialized expertise in Dealmaking - Licensing - Commercial strategy applying deep market insights from Regulated to Emerging markets globally.

Through transparent, compliant and collaborative communication, we accelerate global asset commercialization from Portfolio building to Strategy, Business development and Alliance management.

about-us-image
Rajiv S - Partner

Leadership

Leading the way with Partnership for upward

"We are passionately building unwavering partnerships and sharp strategies to unlock breakthrough, clinically proven therapies for markets that need them most. Excited to drive the next wave of global healthcare innovation!"

- Rajiv S

Global Business Development Head

Our Leadership Team's core expertise:

  • Global Business Development (In & Out Licensing)
  • Deal Making & Pricing Strategy
  • M&A Target Profiling
  • Commercial & Cluster Strategy
  • Clinical Development Partnerships
  • Portfolio Management
  • Alliance Management

Purpose

Creating a pillar of strength in Pharma

At Vyarx, our purpose is to accelerate access to innovation for patients in need by making swift, informed decisions and building powerful global connections. We are committed to bridging markets and ensuring that breakthrough therapies reach those who need them most, uniting expertise and opportunity to make healthcare truly borderless.
Let the informed stay long.

purpose-illustration

News

What’s new

Pharma Expo April 2026
EVENT - 23-25 Apr 2026

Vyarx at Pharma Expo April 2026

Vyarx will be at India Pharma Expo 2026 from 23-25 Apr 2026...

Oveporexton
Molecule Highlight

Oveporexton

Takeda's oveporexton (TAK-861), a first-in-class oral orexin receptor 2 agonist targeting narcolepsy type 1.

Bemarituzumab
Molecule Highlight

Bemarituzumab

Amgen's bemarituzumab, a humanized monoclonal antibody targeting FGFR2b for gastric cancer treatment.

Get in Touch

We'd love to hear from you. Please fill out the form below and we'll get back to you shortly.

✓

Thank You!

Your message has been received. We'll get back to you shortly.